Related Experiment Videos
Lymphocyte predominant Hodgkin's disease
Bradley C Ekstrand1, Sandra J Horning
1Division of Oncology, Department of Medicine, Stanford University School of Medicine, 1000 Welch Road, Suite 202, Palo Alto, CA 94304, USA.
Current Oncology Reports
|August 7, 2002
Summary
Lymphocyte predominant Hodgkin's disease (LPHD) is a rare B-cell lymphoma. While typically responding well to treatment, its unique characteristics and late relapses prompt reevaluation of aggressive upfront strategies.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- Lymphocyte predominant Hodgkin's disease (LPHD) is a distinct B-cell lymphoma.
- It presents uniquely in younger males with indolent, peripheral lymphadenopathy.
- Distinguished by immunophenotype (CD20+, CD15-, CD30-) from classical Hodgkin's disease subtypes.
Purpose of the Study:
- To highlight the unique clinicopathologic features of LPHD.
- To discuss the implications of late relapses and treatment toxicity.
- To explore emerging molecular insights and targeted therapies for LPHD.
Main Methods:
- Review of LPHD characteristics.
- Analysis of treatment response and relapse patterns.
- Discussion of immunophenotypic distinctions.
Main Results:
- LPHD patients exhibit unique immunophenotypes and clinical presentations.
- Despite initial treatment success, continuous late relapses occur.
- Benign relapse nature and late toxicities question aggressive upfront treatment.
Conclusions:
- LPHD requires consideration of its unique features in treatment planning.
- The balance between efficacy, late toxicity, and relapse patterns is critical.
- Novel therapies and molecular understanding offer future treatment improvements.